Home Cart Sign in  
Chemical Structure| 1093070-14-4 Chemical Structure| 1093070-14-4

Structure of PLpro inhibitor
CAS No.: 1093070-14-4

Chemical Structure| 1093070-14-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with IC50 of 2.6 μM.

Synonyms: PLpro Inhibitor 6; KOM-70144; PLpro inhibitor, KOM70144

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PLpro inhibitor

CAS No. :1093070-14-4
Formula : C22H22N2O2
M.W : 346.42
SMILES Code : O=C(C1=CC(NC(C)=O)=CC=C1C)N[C@H](C)C2=C(C=CC=C3)C3=CC=C2
Synonyms :
PLpro Inhibitor 6; KOM-70144; PLpro inhibitor, KOM70144
MDL No. :MFCD12547684
InChI Key :KGPYBLOBHQLIET-OAHLLOKOSA-N
Pubchem ID :44235889

Safety of PLpro inhibitor

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Vero cells 11 µM and 33 µM 72 hours Assess the antiviral activity of PLpro inhibitors EMBO J. 2020 Sep 15;39(18):e106275.
Vero E6 cells 68.2 µM Evaluate the antiviral effect of GRL0617 (1) in Vero E6 cells Sci Adv. 2024 Aug 30;10(35):eado4288.
Vero cells 10 µM 24 hours Evaluate the inhibitory effect of F0213 on SARS-CoV-2 NP antigen, results showed significant inhibition of viral replication. Protein Cell. 2022 Dec;13(12):940-953.
HEK293T cells 20-80 µM 24 hours To assess whether GRL0617 can inhibit the in cyto deubiquitinating and deISGylating activity of SARS-CoV-2 PLpro. Results showed that GRL0617 partially recovered poly-ubiquitin-conjugates and ISG15-conjugates. Nat Commun. 2021 Jan 20;12(1):488.
Vero E6 cells 0.17 to 3.18 µM 24 hours Evaluate antiviral activity, all four compounds showed strong antiviral effects Protein Cell. 2021 Nov;12(11):877-888.
Vero E6 cells 25, 75, 100, 200, 300, 400 µM 24 hours To evaluate the antiviral potential of ATA, IC50 was 50 μM Int J Biol Macromol. 2023 Mar 1;230:123347.
HEK293T cells 10 µM 24 hours Evaluate the inhibitory effect of PLpro inhibitors on nsp1-nsp2 protein cleavage Cell Chem Biol. 2021 Jun 17;28(6):855-865.e9.
Differentiated normal human bronchial epithelial (dNHBE) cells 13.9 nM 3 days Evaluate the antiviral effect of PF-07957472 (4) in dNHBE cells Sci Adv. 2024 Aug 30;10(35):eado4288.
Vero 0.41 µM 4 days Determine antiviral EC50 of WEHI-P4 by plaque assay, showing EC50 of 410 nM Nat Commun. 2025 Apr 3;16(1):2900.
Vero E6 cells 100 µM 48 hours To evaluate the antiviral activity of GRL0617 against SARS-CoV-2. Results showed that 100 μM GRL0617 inhibited over 50% of viral replication. Nat Commun. 2021 Jan 20;12(1):488.
Vero E6 cells 1.1 µM 48 hours Assessed the protective effect of compound 7 against SARS-CoV-2-induced cell death, with an EC50 of 1.1 μM, comparable to remdesivir Nat Commun. 2023 Mar 28;14(1):1733.
A549-hACE2 cells 2.5 µM (EC50) 48 hours Evaluate the antiviral activity of PLpro inhibitors in A549-hACE2 cells, results showed compound 10 exhibited broad-spectrum antiviral effects against SARS-CoV-2 original strain and variants J Med Chem. 2024 Aug 22;67(16):13681-13702.
HACE2-HeLa cells 5 µM 48 hours Evaluate the inhibitory effect of PLpro inhibitors on SARS-CoV-2 replication Cell Chem Biol. 2021 Jun 17;28(6):855-865.e9.
VeroE6-TMPRSS2 cells 2.2–4.8 µM 72 hours Evaluate the inhibitory effect of F0213 on SARS-CoV-2 variants, results showed dose-dependent inhibition against all variants. Protein Cell. 2022 Dec;13(12):940-953.
LT-A549 8.352 µM 72 hours Evaluation of cytotoxicity of compound 5 on LT-A549 cells, showing CC50 of 45.775 μM. Eur J Med Chem. 2023 Apr 5;252:115272.
Wi-38 10.356 µM 72 hours Evaluation of cytotoxicity of compound 5 on Wi-38 cells, showing CC50 of 51.781 μM. Eur J Med Chem. 2023 Apr 5;252:115272.
Caco-2 cells 0.26 µM Evaluated the antiviral activity of compound 7 in human cells, with an EC90 of 0.26 μM against the USA-WA1/2020 strain Nat Commun. 2023 Mar 28;14(1):1733.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice SARS-CoV-2 MA10 infection model Intraperitoneal injection 10 mg/kg Twice daily for 2 days Evaluate the antiviral efficacy of PLpro inhibitors in Mice model, results showed compound 10 significantly reduced lung viral load J Med Chem. 2024 Aug 22;67(16):13681-13702.
C57BL/6 mice SARS-CoV-2 P21 infection severe disease model Oral 100 mg/kg and 150 mg/kg Administered at 6, 24, and 48 hours post-infection Evaluate efficacy of WEHI-P8 in severe SARS-CoV-2 infection model, results showed both 100 mg/kg and 150 mg/kg doses significantly reduced viral load and alleviated lung inflammation Nat Commun. 2025 Apr 3;16(1):2900.
Syrian hamsters SARS-CoV-2 infection model Oral 15, 30, 45 mg/kg Once daily for 4 days To evaluate the in vivo antiviral potential of ATA, results showed reduction in viral load in throat swabs but no significant changes in lung tissues Int J Biol Macromol. 2023 Mar 1;230:123347.
Mice BALB/c mice Oral 20, 50, 150 mg/kg Twice daily for 4 days Evaluate the antiviral effect of PF-07957472 in a Mice infection model Sci Adv. 2024 Aug 30;10(35):eado4288.
K18-hACE2 transgenic mice SARS-CoV-2 XBB.1 infection model Oral 25 mg/kg, 50 mg/kg, 100 mg/kg Treatment started 2 hours post-infection and lasted for 4 days Evaluate the antiviral efficacy of GZNL-P36 in SARS-CoV-2 infected Mice model, showing significantly improved survival and notable reductions in lung viral loads and lesions. Nat Commun. 2024 Nov 23;15(1):10169

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.89mL

0.58mL

0.29mL

14.43mL

2.89mL

1.44mL

28.87mL

5.77mL

2.89mL

References

 

Historical Records

Categories